Considering that altered BCAA metabolism is a pathognomonic feature of insulin resistance and T2D, the BCAA to BCHA conversion could possibly be harnessed for therapeutic applications23,62–68. The gene discussed is ARID4B; the disease is type 2 diabetes mellitus.